Trifluoperazine 2HCl: A Potent Dopamine D2 Receptor Antagonist for Neuropharmacology and Immune Modulation

Executive Summary: Trifluoperazine 2HCl is a research-grade phenothiazine derivative with an IC50 of 1.1 nM for dopamine D2 receptor inhibition, facilitating precise dopaminergic pathway modulation (APExBIO). The compound is highly soluble (≥24 mg/mL in DMSO, ≥48 mg/mL in water) and is stable when stored at -20°C. It induces autophagy and reactive oxygen species (ROS) in macrophages, supporting studies in host-pathogen interactions (Qiu et al., 2025). Trifluoperazine 2HCl is applicable in neuropharmacology, oncology, and immunology research. Freshly prepared solutions are recommended to ensure experimental reproducibility.

Biological Rationale

Trifluoperazine 2HCl (SKU: B1397) is a solid phenothiazine compound, chemically defined as 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride (C21H24F3N3S·2HCl; MW: 480.42). It serves as a potent dopamine D2 receptor antagonist, with a measured IC50 of 1.1 nM determined in radioligand binding assays (APExBIO). Dopaminergic signaling is fundamental in regulating neuronal excitability, synaptic plasticity, and immune cell function, making D2 antagonists critical tools in neuropharmacology assays and dopaminergic signaling pathway modulation (Related Article). The compound also enables investigation of host-directed antibacterial mechanisms, including macrophage activation and pathogen clearance.

Mechanism of Action of Trifluoperazine 2HCl

Trifluoperazine 2HCl competitively inhibits dopamine at the D2 receptor, blocking downstream G protein-coupled signaling. This action disrupts dopaminergic transmission in neuronal and non-neuronal cells. In immune cells, particularly macrophages, phenothiazine derivatives including Trifluoperazine 2HCl induce autophagy and increase intracellular ROS, thereby enhancing antibacterial defense (Qiu et al., 2025). This effect is independent of direct bactericidal activity and is classified as host-directed therapy (HDT). The compound also influences calcium signaling, calmodulin inhibition, and can alter cell cycle dynamics in some cancer cell lines (Enhancing Dopaminergic and Host-Directed Assays).

Evidence & Benchmarks

• Trifluoperazine 2HCl inhibits dopamine D2 receptors with an IC50 of 1.1 nM at 25°C, pH 7.4, in in vitro radioligand binding assays (APExBIO).
• It is highly soluble in DMSO (≥24.02 mg/mL), water (≥48 mg/mL), and ethanol (≥7.26 mg/mL with sonication) at room temperature, facilitating diverse assay conditions (APExBIO).
• Phenothiazine compounds, including Trifluoperazine, induce autophagy and ROS in murine and human macrophages, leading to enhanced antibacterial activity against S. Typhimurium in vitro and in vivo (Qiu et al., 2025).
• Co-treatment with autophagy or ROS inhibitors abrogates the antibacterial effect of phenothiazines, confirming the mechanistic requirement for both pathways (Qiu et al., 2025).
• Trifluoperazine 2HCl is used as a reference antagonist in dopamine receptor antagonist assays and neuropharmacology research workflows (Harnessing Dopaminergic Pathways).

Applications, Limits & Misconceptions

Trifluoperazine 2HCl is validated for use in:

• Neuropharmacology research to dissect dopaminergic signaling and screen for D2 receptor antagonist activity.
• In vitro and in vivo models of neurological disorders, including schizophrenia and Parkinson's disease.
• Host-pathogen interaction studies, especially for macrophage-driven clearance of intracellular bacteria via autophagy and ROS induction (Qiu et al., 2025).
• Experimental oncology, including medulloblastoma therapeutic screening.

Compared to Trifluoperazine 2HCl: A Versatile Dopamine D2 Receptor Inhibitor, this article provides updated benchmarks on ROS/autophagy induction and clarifies boundaries for host-pathogen applications.

Common Pitfalls or Misconceptions

• Trifluoperazine 2HCl does not exhibit direct bactericidal or antibiotic activity; its effects are host-mediated (Qiu et al., 2025).
• Long-term storage of prepared solutions (even at -20°C) may reduce activity; always use freshly prepared stocks (APExBIO).
• Dose-response relationships may vary between cell types and organisms; cross-validation is necessary (Enhancing Dopaminergic and Host-Directed Assays).
• The compound should not be used as a clinical drug without appropriate regulatory approval; it is for research use only.
• False positives in ROS or autophagy assays may arise if solvents are not matched in controls.

Workflow Integration & Parameters

Trifluoperazine 2HCl is supplied as a solid and should be dissolved in DMSO, water, or ethanol at concentrations suited to the intended assay (typically 1–20 μM for cell-based studies). Storage at -20°C is optimal for solid form; avoid repeated freeze-thaw cycles. For in vitro work, prepare stocks fresh, filter-sterilize if required, and use within 24 hours. For in vivo studies, dosing should be guided by published pharmacokinetic data and ethical protocols. APExBIO provides validated data sheets and batch-specific documentation for reproducibility (Trifluoperazine 2HCl product page).

This article updates protocol integration strategies compared to Enhancing Dopaminergic and Host-Directed Assays with Trifluoperazine 2HCl by emphasizing solution stability and solvent compatibility.

Conclusion & Outlook

Trifluoperazine 2HCl, as distributed by APExBIO, is a robust dopamine D2 receptor antagonist for research in neuroscience, immunology, and oncology. Its ability to induce autophagy and ROS in macrophages positions it as a valuable host-directed tool in infectious disease and cancer models. Product-specific parameters, such as solubility and storage, are critical for experimental reproducibility. Ongoing research will further refine its applications in translational science and therapeutic screening. For detailed protocols and batch information, refer to the official Trifluoperazine 2HCl product page.